--- title: "Cibus Earnings Call: Cash Extended, Execution Critical" type: "News" locale: "en" url: "https://longbridge.com/en/news/286978622.md" description: "Cibus, Inc. reported its Q1 earnings, raising $37 million to extend its cash runway to late Q1 2027. The company noted improved cost control, with operating expenses down nearly $8 million, but acknowledged ongoing financial risks and uncertainty in revenue generation. Key developments include progress in its rice program in LATAM and advancements in sustainable ingredients. However, the U.S. rice launch has been delayed to 2029, and profitability remains distant with a net loss of $21.2 million." datetime: "2026-05-20T00:02:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286978622.md) - [en](https://longbridge.com/en/news/286978622.md) - [zh-HK](https://longbridge.com/zh-HK/news/286978622.md) --- # Cibus Earnings Call: Cash Extended, Execution Critical Cibus, Inc. ((CBUS)) has held its Q1 earnings call. Read on for the main highlights of the call. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Cibus’ latest earnings call struck a cautiously optimistic tone, blending clear execution gains with lingering financial risks. Management highlighted fresh capital, tighter cost control, and tangible technical and regulatory progress, especially in rice and sustainable ingredients. Yet they acknowledged that the path to meaningful revenue remains uncertain and that the company’s future hinges on disciplined execution. ## Capital Raise Extends Runway, But Not Comfortably Cibus raised about $37 million in gross proceeds across two public offerings, ending Q1 2026 with $30.3 million in cash and equivalents. Management believes this, combined with cost savings, will fund operations into late Q1 2027, giving the company some breathing room but not eliminating the need for stronger revenue or future financing. ## Sharp Cost Cuts Narrow Losses The company delivered a material reset in its cost base, with combined operating expenses down nearly $8 million year over year. R&D fell to $8.7 million and SG&A to $5.1 million, driving a net loss improvement to $21.2 million and cutting loss per Class A share to $0.33, as management targets 2026 net cash usage of about $30 million or less. ## Rice Program in LATAM Gains Commercial Traction Cibus reported meaningful commercial progress in its herbicide-tolerant rice program focused on Latin America. A nonbinding LOI with Interoc, an import permit in March, and delivery of gene-edited rice materials in May support a 2027 launch in Ecuador and Colombia, with phased expansion and seven active seed-company relationships across LATAM and the U.S. ## Sustainable Ingredients Edge Closer to Market The Sustainable Ingredients business is moving from validation toward scale, supported by pre-commercial pilot runs and early customer payments. Cibus recognized a catch-up payment in Q1 and expects additional scale-up orders for its initial biofragrances in the second half of 2026, eyeing a potential $20 million to $40 million annual royalty opportunity in a global fragrance market above $65 billion. ## Platform Advances Strengthen Technical Edge On the technology front, Cibus achieved an order-of-magnitude improvement in rice editing efficiency by leveraging optimization and AI or machine learning. It also reached single-cell regeneration in a wheat cultivar, opening the door to wheat trait development, while advancing soybean HT2 and several canola traits under externally supported programs. ## Regulatory Tailwinds Build Across Key Markets Regulatory momentum was a bright spot, with Cibus citing 17 positive USDA-APHIS determinations in the U.S. and favorable decisions in Ecuador and Peru that treat its rice traits as equivalent to conventional breeding. Progress on New Genomic Techniques legislation in the EU, backed by key institutions, is improving clarity for future commercialization across multiple regions. ## Runway Dependent on Revenue Execution Despite the capital raise and cost cuts, management emphasized that the current cash balance offers only a limited runway. The outlook to late Q1 2027 assumes that near-term commercial revenues, especially from rice and sustainable ingredients, ramp as planned and that costs stay contained, leaving the door open to future financing if plans slip. ## U.S. Rice Launch Pushed Out One Year Investors will have to wait longer for U.S. rice economics, as Cibus shifted its targeted launch from 2028 to 2029. The delay stems from the registration timeline for the associated herbicide with partner Albaugh, a regulatory gating item that remains largely outside Cibus’ control and underscores the execution risk in its rice strategy. ## Revenue and Partnerships Still Nascent While commercial frameworks are forming, many of Cibus’ key agreements remain at the LOI or partner-funded development stage, including the Interoc arrangement. Current revenues are modest, and the more substantial royalty streams management envisions will depend on partners’ product launches and regulatory and chemical alignment over the coming years. ## Profitability Still Distant Amid Interest Burden Cibus’ net loss, though reduced, remained sizeable at $21.2 million in the quarter, reminding investors that profitability is still far off. An additional pressure point is interest on royalty liabilities, which rose to $9.1 million, representing ongoing non-operating costs that weigh on the income statement even as operations become leaner. ## Lean Cost Base May Constrain Future Pace The company’s aggressive reductions in R&D and SG&A are central to its improved P&L and extended runway but may come with trade-offs. Management acknowledged that further cuts, if needed, could constrain development speed, leaving Cibus to balance discipline with the need to advance multiple crop and ingredient programs in parallel. ## Guidance Emphasizes Controlled Burn and Key Milestones Looking ahead, Cibus reaffirmed its plan to keep 2026 net cash usage near $30 million or less, with burn expected to trend down from Q1 into Q2 and align with targets in the back half of the year. Commercially, management is steering toward a 2027 LATAM rice launch, a now-2029 U.S. rice debut, and biofragrance scale-up orders in late 2026, while continuing to bank on regulatory momentum and partner execution to unlock larger royalty streams. Cibus’ earnings call painted a picture of a company that has tightened its finances and sharpened its focus but remains early in monetizing its platform. Execution on rice in LATAM, the sustainable ingredients ramp, and regulatory-driven opportunities will be crucial, and investors will watch closely to see if the current momentum can translate into durable revenue before the cash runway narrows. ### Related Stocks - [CBUS.US](https://longbridge.com/en/quote/CBUS.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [Cibus Q1 revenue rises and beats analyst estimates](https://longbridge.com/en/news/286463305.md) - [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md) - [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md) - [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md) - [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)